|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
2
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion
3
Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last
4
Catalent Announces Expanded Partnership with Nanoscope Therapeutics
5